SynaptixBio receives incurable disease research boost
The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development
Read More
Tag: incurable
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
